EULAR 2019: reviewing big pharma and biosimilar takeaways from Spain

Now that the warming Spanish sun has gone down on EULAR 2019, it’s worth considering what emerged of note from some of rheumatology’s leading players at the event in Madrid.

And – in a field where so many big-selling biologics are at the end of their patents – what did the biosimilar companies do to close in on more sales of the reference products?

The Pharma Letter was on site in Madrid to speak to some of the companies and take in the data being presented to Europe’s rheumatologists, patient groups and other interested parties.